Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 99m Tc-sestamibi, 99m-Tc sestamibi, 99mTc sestamibi + [22] |
Target- |
Mechanism SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (21 Dec 1990), |
Regulation- |
Molecular FormulaC36H66N6O6Tc |
InChIKeyZBTQTVSNLRPJHI-ZKPGHZHMSA-N |
CAS Registry109581-73-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Technetium Tc-99M Sestamibi Kit |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diagnostic agents | JP | 02 Apr 1993 | |
Cardiomyopathies | US | 21 Dec 1990 | |
Contrast agents | US | 21 Dec 1990 | |
Heart Diseases | CN | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mucocutaneous Lymph Node Syndrome | Phase 3 | US | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Phase 3 | BR | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Phase 3 | CA | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Phase 3 | PH | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Phase 3 | KR | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Phase 3 | TW | 01 Aug 2005 | |
Mucocutaneous Lymph Node Syndrome | Phase 3 | TH | 01 Aug 2005 |
Not Applicable | - | zmtnlmrgjl(tivdmhzntm) = gpksamashx gasyhrdprh (uonhcaiiiu ) View more | - | 01 May 2024 | |||
zmtnlmrgjl(tivdmhzntm) = zwiibdsuvz gasyhrdprh (uonhcaiiiu ) View more | |||||||
Phase 4 | 4 | njmhthtyqa(wlgexqecaj) = flokbqurrp ulfjhekcik (uitoweckbi, oycypeeraa - mctyubthrh) View more | - | 26 Jul 2022 | |||
Not Applicable | 30 | afsdzedvmf(vmyqmaybyf) = bwcskfdadl wzfwsyzjkl (deupqsxpcb ) | - | 28 Aug 2020 | |||
123I-BMIPP | afsdzedvmf(vmyqmaybyf) = caclhaxwiv wzfwsyzjkl (deupqsxpcb ) |